Corvus Pharmaceuticals
CRVS
52 hedge funds and large institutions have $44.6M invested in Corvus Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 11 increasing their positions, 6 reducing their positions, and 7 closing their positions.
214% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 7
83% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 6
41% more funds holding
Funds holding: 37 → 52 (+15)
6% more capital inflows, than outflows
Capital inflows: $7.58M | Capital outflows: $7.17M
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less call options, than puts
Call options by funds: $266K | Put options by funds: $272K
2.79% less ownership
Funds ownership: 44.65% → 41.86% (-2.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Samlyn Capital
New York
|
+$4.38M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$621K |
| 3 |
TL
TowerView LLC
New York
|
+$426K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$384K |
| 5 |
MA
MYDA Advisors
Woodmere,
New York
|
+$208K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CA
CHI Advisors
New York
|
-$4.44M |
| 2 |
Millennium Management
New York
|
-$1.85M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$499K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$153K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$104K |
CRVS Hedge Fund Activity: Q2 2023 in Review
52 of the 6,387 institutional investors tracked by Wall St. Rank reported a position in Corvus Pharmaceuticals (CRVS) for Q2 2023, worth a combined $44.6M — up 136% from $18.9M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new CRVS positions and 7 closed out — a net gain of 15 holders — while 11 added to existing stakes and 6 trimmed.
The largest buyer was Samlyn Capital, opening a new position worth an estimated $4.38M. The largest seller was CHI Advisors, cutting an estimated $4.44M.
- 52 institutional investors held Corvus Pharmaceuticals (CRVS) as of Q2 2023, up from 37 in Q1 2023.
- Funds reported $44.6M of Corvus Pharmaceuticals stock for Q2 2023, up 136% quarter-over-quarter.
- 22 funds opened new Corvus Pharmaceuticals positions in Q2 2023 and 7 closed out, a net change of +15 holders.
- The largest Corvus Pharmaceuticals buyer in Q2 2023 was Samlyn Capital, an estimated $4.38M added.
- The largest Corvus Pharmaceuticals seller in Q2 2023 was CHI Advisors, an estimated $4.44M sold.
Based on aggregated 13F filings for Q2 2023.